文献速递前列腺癌

前列腺癌血清嗜铬粒蛋白A与神经元特异性烯醇化酶水平分析

Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer.
PubMed 文献 · BJU Int · 2020-05-14

本研究分析了395例前列腺癌患者的1095份血清样本,比较局限性与去势抵抗性前列腺癌中嗜铬粒蛋白A(CGA)和神经元特异性烯醇化酶(NSE)水平。结果发现去势抵抗组基线CGA和NSE显著高于激素初治的局限性组(P<0.001),高基线CGA与总生存期差独立相关,尤其在阿比特龙/恩扎卢胺队列中,3个月CGA升高>50%与生存差相关。提示血清CGA可能有助于晚期前列腺癌的个体化治疗与监测。

要点

  • 去势抵抗性前列腺癌患者基线CGA和NSE水平显著高于激素初治局限性患者。
  • 高基线CGA水平与多西他赛及阿比特龙/恩扎卢胺队列的总生存期差独立相关。
  • 阿比特龙/恩扎卢胺治疗3个月CGA升高>50%与生存差相关,尤其在高基线CGA患者中。

核心结论

  • 去势抵抗性前列腺癌中神经内分泌标志物水平较激素初治者高2-3倍,支持雄激素剥夺治疗下神经内分泌转分化。
  • 高基线CGA且在阿比特龙/恩扎卢胺治疗期间CGA进一步升高的患者预后最差。
  • 血清CGA水平可能有助于晚期前列腺癌的治疗选择和监测。

研究设计与样本

  • 回顾性分析395例前列腺癌患者的1095份血清样本,分为根治性前列腺切除术队列(n=157,临床局限性)、多西他赛队列(n=95,转移性去势抵抗性)和阿比特龙/恩扎卢胺队列(n=143,转移性去势抵抗性)。
  • 使用KRYPTOR方法测定CGA、NSE和总PSA水平。

主要发现

  • 去势抵抗组(多西他赛和阿比特龙/恩扎卢胺队列)基线CGA和NSE水平高于激素初治的临床局限性前列腺癌组(P<0.001)。
  • 高基线CGA水平在多西他赛和阿比特龙/恩扎卢胺队列中均与总生存期差独立相关,在阿比特龙/恩扎卢胺队列中关联更强。
  • 在阿比特龙/恩扎卢胺队列中,3个月时CGA升高>50%与生存差相关,尤其在高基线CGA患者中。

临床怎么用

  • 对于接受阿比特龙或恩扎卢胺治疗的转移性去势抵抗性前列腺癌患者,可考虑监测血清CGA水平以辅助预后评估。
  • 基线CGA高且治疗3个月内CGA升高>50%的患者预后较差,可能需要更密切的随访或调整治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess chromogranin A (CGA) and neuron-specific enolase (NSE) levels and changes in these at different stages of prostatic adenocarcinoma (PCA). METHODS: Overall, 1095 serum samples from 395 patients, divided into three treatment groups, were analysed; the radical prostatectomy (RP) cohort (n = 157) included patients with clinically localized PCA, while the docetaxel (DOC) and the abiraterone (ABI)/enzalutamide (ENZA) cohorts included 95 and 143 patients, respectively, with metastatic castration-resistant prostate cancer. CGA, NSE and total PSA levels were measured using the KRYPTOR method. RESULTS: Baseline CGA and NSE levels were higher in castration-resistant (DOC and ABI/ENZA cohorts) than in hormone-naïve, clinically localized PCA (P < 0.001). High baseline CGA levels were independently associated with poor overall survival in both the DOC and the ABI/ENZA cohorts, with a stronger association in the ABI/ENZA cohort. In the ABI/ENZA cohort, a > 50% CGA increase at 3 months was associated with poor survival, especially in patients with high baseline CGA levels. CONCLUSIONS: The two- to threefold higher neuroendocrine marker levels in castration-resistant compared to hormone-naïve PCA support the presence of neuroendocrine transdifferentiation under androgen deprivation therapy. Our results showed patients with high baseline CGA levels who experienced a further CGA increase during ABI and ENZA treatment had the poorest prognosis. Serum CGA levels could help in tailoring and monitoring therapy in advanced PCA.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Szarvas T, Csizmarik A, Fazekas T, et al. Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer. BJU Int. 2020. PMID: 32314509. doi:10.1111/bju.15086

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。